Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
01/2001
01/17/2001CN1279964A Method for removing farm chemical ingredients from ginseng extract
01/17/2001CN1279953A Application of seeweed polyose sulphate
01/17/2001CN1279952A Clindamycin phosphate preparation for transfusion
01/17/2001CN1279951A Use of ecdysterone in preparing medicine for angiocardiopathy
01/17/2001CN1279950A Sigma-receptor acting medicine with triterpene compound structure
01/17/2001CN1279949A Compound hypoglycemic nutrient
01/17/2001CN1279948A Hypoglycemic for type II diabetes
01/17/2001CN1279947A Eye preparation of zinc norfloxacin
01/17/2001CN1279946A Berberine hydrochloride suppository and its producing method
01/17/2001CN1279945A Gastric floating slow-releasing tinidazole capsule and its preparing method
01/17/2001CN1279944A Effervescent tablets for curing vaginitis and its preparing method
01/17/2001CN1279942A Medicinal aerosol for curing respiratory system disease
01/17/2001CN1279939A Local use cosmetic compositions containing benzaldoximes compounds
01/17/2001CN1060782C Preparation and application of sargassum polysaccharide complex
01/17/2001CN1060781C Phosphonomonoester nucleic acids, process for treir preparation, and their use
01/17/2001CN1060778C Cephalosporin derivatives
01/17/2001CN1060776C Procell for manufactare of imidazo benzodiazepine derivatives
01/17/2001CN1060775C Fused troane-derivatives as neurotransmitter reuptake inhibitors
01/17/2001CN1060774C Process for preparation of enantionerically pure imidazolyl compounds
01/17/2001CN1060773C Naphthamide derivatives of 3-beta-amino azabicyclo octane or nonane as heuroleptic agents
01/17/2001CN1060772C New Indole, Indazole and benzisoxazole compounds, their process of preparation and pharmaceutical compositions which contain them
01/17/2001CN1060770C Crystalline anhydrous mycophenolate mofetil and intravenous formulation thereof
01/17/2001CN1060768C Pyrazoles and pyrazolopyrimidines
01/17/2001CN1060767C Substituted benzene sulfonyl usea and benzene sulfonyl thiourea and mfg, method and use as raw material for medicine and medicine containing them
01/17/2001CN1060764C Ortho-substituted benzoylguanidine, preparation method, use as medicine or diagnostic reagent and medicine containing them
01/17/2001CN1060763C Urea-substituted benzoylguanidines, process for their preparation, and use and pharmaceutical containing them
01/17/2001CN1060761C New aryl (alkyl) propylamides, process for preparing them and pharmaceutical compositions containing them
01/17/2001CN1060679C Use of combination of angiotensin-converting enzyme inhibitor and calcium antagonist for treatment of proteinuria
01/17/2001CN1060675C Medicine for treating epilepsy
01/17/2001CN1060652C Rhinitis liniment and its preparation
01/17/2001CN1060649C Medicine for curing vitiligo
01/17/2001CN1060646C Injection solution for giving up addiction of drug addict and its preparing method
01/16/2001USRE37020 Administering an elderly patient a protein source, a lipid source includes triglycerides and a carbohydrate source includes a source of dietary fiber, preferably, the protein source includes atleast 18% of the total calories as
01/16/2001US6175035 Method of producing betulinic acid
01/16/2001US6175023 Synthesis of water soluble 9-dihydro-paclitaxel derivatives from 9-dihydro-13-acetylbaccatin III
01/16/2001US6175021 Human non-pancreatic secretory phospholipase a2 (spla2); inhibits release of arachidonic acid to treat septic shock; ((3-(2-amino-1,2-dioxoethyl)-2-methyl-1-(phenylmethyl)-1h-indol-4 -yl)oxylacetic acid, for example
01/16/2001US6175014 Process for the preparation of lactam derivatives
01/16/2001US6175013 1-(2-methoxybenzyl)-2-((4-phenyl-1-piperazinyl)methyl)-4-(1h -indol-3-ylmethyl)-2-imidazoline, for example; adminstering to treat anxiety, depression, psychosis, and schizophrenia
01/16/2001US6174994 7TM receptor (H2CAA71)
01/16/2001US6174925 Reducing insulin resistance in humans in whom impaired glucose tolerance or non-insulin dependent diabetes mellitus have not presented but in whom there is increased risk of developing such conditions by administering sibutramine analogue
01/16/2001US6174924 Treating nerve cell death comprising administering to a subject exhibiting symptoms of nerve cell death or susceptible to nerve cell death a substituted guanidine compound
01/16/2001US6174923 Administering ethynyl alanine amino diol compound for treating hypertension
01/16/2001US6174921 Antitumor compositions and methods of treatment
01/16/2001US6174917 Treatment of liver disease such as cirrhosis of liver, toxic and medicamentary liver damage, liver-parenchymic disorder or hepatitis, by oral administrering low dose of a vasodilating agent which selectively increases supply of oxygenated blood
01/16/2001US6174914 Method of inhibiting cytokine release from human ocular cells
01/16/2001US6174913 Treating tumor by administering compounds e.g.:2-acetyl-naphtho(2,3-b)thiophene-4,9-dione; 2,7-diacetyl-naphtho(2,3-b)thiophene-4,9-dione
01/16/2001US6174910 Treating pathological symptoms of vascular proliferation disorders which can be reduced or inhibited by apoptosis, by administering at.sub.1(angiotensin) receptor antagonist compound such as valsartan, irbesartan, losatran etc.
01/16/2001US6174909 For treating analgesia, psychosis, convulsions, epilepsy, anxiety, muscular and movement disorders, spastic disorders or symptoms of huntington's or parkinsons disease
01/16/2001US6174908 Treating disease, condition, or disorder which responds to inhibition of potassium channel function by administering thiazolidone or metathiazonone compound, its salt, amide, ester, complex, chelate, hydrate, stereoisomer, metabolite
01/16/2001US6174906 Endothelin receptor antagonists
01/16/2001US6174904 Treating glycometabolism disorders in mammals by administering therapeutically effective amount of an insulin sensitivity enhancer in combination with an .alpha.-glucosidase inhibitor
01/16/2001US6174903 Imidazolidin-4-one derivatives useful as anticancer agents
01/16/2001US6174902 Treating ulcers by administering to human therapeutically effective amount of optically pure r(+)isomer of rabeprazole, or a pharmaceutically acceptable salt
01/16/2001US6174899 Orally administered analgesic composition comprising myfadol
01/16/2001US6174898 Method of treating filariae
01/16/2001US6174897 For treatment of brain dissorders such as dementia, depression, myotonic dystrophy, alcoholism and other addiction diseases, sleep disturbances and bronchial asthma, presenile alzheimer's disease
01/16/2001US6174896 Quinuclidine derivatives and medicinal composition thereof
01/16/2001US6174895 1-aryl-3-arylmethyl-1,8-naphthyridin-4(1H)-ones
01/16/2001US6174892 Method of treating acne with 5-α reductase inhibitors
01/16/2001US6174891 Antipruritic agent
01/16/2001US6174890 A synergistic biological, neurometabolic and celltrophic composition comprising antioxidative and -catabolic stress (methionine),-anabolic drugs, vasodilative and normo-lipidemic drugs (nicotinic acid), energoactive and antitoxic
01/16/2001US6174889 Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
01/16/2001US6174888 Potent purine nucleoside phosphorylase inhibitors; inhibitors of t-cell formation, i.e., immunosuppressants; transplant rejection; autoimmune diseases, e.g., rheumatoid diseases, psoriasis, dermatitis, crohn's disease, uveitis;
01/16/2001US6174887 Amide compounds and use of the same
01/16/2001US6174886 Antipsychotic use of triazolo-pyridazine derivatives
01/16/2001US6174884 1,5-dihydro-pyrazolo[34-D]-pyrimidinone derivatives
01/16/2001US6174883 3-substituted-2-oxindoles derivatives
01/16/2001US6174882 Treating psychosis, acute mania, schizophrenia, excessive agression, substance abuse and fungal dermatitis; bipolar, autistism, tic, functional bowel and attention deficit hyperactivity disorders, anxiolytic agents; antidepressants
01/16/2001US6174881 Hydroxymethylimidazodiazepines and their esters
01/16/2001US6174880 Method for treatment of painful fibromuscular disorder
01/16/2001US6174878 Topical use of kappa opioid agonists to treat otic pain
01/16/2001US6174876 Use of boswellic acid for treating brain tumors
01/16/2001US6174875 Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke
01/16/2001US6174874 Phosphonic acids derivatives as inhibitors of protein tyrosine phosphate 1B (PTP-1B)
01/16/2001US6174873 Oral administration of adenosine analogs
01/16/2001US6174869 Method for enhancing neurone survival and agents useful for same
01/16/2001US6174868 Compositions and methods for treatment of hepatitis C virus-associated diseases
01/16/2001US6174867 Inhibition of the binding of a toxin or organism to its corresponding cell surface receptor; e.g., heat-labile enterotoxin or cholera toxin or enterovirulent organisms; bactericides, viricides, fungicides
01/16/2001US6174865 Method of treating hypertriglyceridemia with an erythromycin compound
01/16/2001US6174864 Methods for the prevention or treatment of inflammatory bowel diseases
01/16/2001US6174863 Carbohydrate derivatives
01/16/2001US6174855 Pharmaceutical compositions comprising thrombin inhibitors and their use in the control of wound healing processes
01/16/2001US6174714 Lyss
01/16/2001US6174687 Methods of identifying lung homing molecules using membrane dipeptidase
01/16/2001US6174560 Substance for lowering high cholesterol level in serum and methods for preparing and using the same
01/16/2001US6174548 Pharmaceutical composition of omeprazole for oral administration which consists essentially of a tabletted core and coating layer
01/16/2001US6174543 Antidiabetic external skin application composition
01/16/2001US6174541 Promoting the healing of a tissue wound comprising delivering a therapeutically effective dosage of indole-3-acetic-acid or its derivatives
01/16/2001US6174539 Localized use of nitric oxide adducts to prevent internal tissue damage
01/16/2001US6174534 Mixture containing fatty acid, ester of polyalkylene ether, hydrogenated palm oil and polyoxyethylenated hydrogenated palm kernel oil, fatty ester, glycerol, fatty alcohol and water
01/16/2001US6174531 Methods of preparation of bioginkgo
01/16/2001US6174524 Gelling ophthalmic compositions containing xanthan gum
01/16/2001CA2314539A1 Use of 4,6-dimethoxy-indole 2-carboxylic acid or its derivatives for the treatment of seborrhoea
01/16/2001CA2314008A1 2-benzimidazolylamine compounds as orl1-receptor agonists
01/16/2001CA2223404C Novel crystal form of anhydrous 7-(¬1.alpha., 5.alpha., 6.alpha.|-6-amino-3-azabicyclo¬3.1.0|hex-3-yl)-6-fluoro-1-(2,4-difluorophenyl)-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid, methanesulfonic acid salt
01/16/2001CA2204355C Peripheral nervous system specific sodium channels, dna encoding therefor, crystallization, x-ray diffraction, computer molecular modeling, rational drug design, drug screening, and methods of making and using thereof
01/16/2001CA2198099C Use of tasteless, hydrolysed collagen and agent containing the same
01/16/2001CA2189916C A new regime for paclitaxel in kaposi's sarcoma patients
01/16/2001CA2150234E Combination of atovaquone with proguanil for the treatment of protozoal infections
01/16/2001CA2140345C Anti-inflammatory compounds for ophthalmic use